Apollo's Bangladesh patient revenue nears pre-crisis peak of ₹450 crore
Apollo Hospitals is in focus in a quarterly results development for Q2FY27.
· BS Companies
Apollo Hospitals expects Bangladesh patient revenue to recover towards its pre-crisis peak of ₹450 crore, while its international patient services business grew nearly 37 per cent in…
Key facts
- Period
- Q2FY27
The analysis
Apollo Hospitals reported ₹450 crore for Q2FY27, with movement of 37% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.9% on the day at ₹8,446.00, and has returned -5.9% over three months. It sits 7% below its 52-week high. The pharma & healthcare sector has moved +1.4% over the same period, so Apollo Hospitals is running 7.3 points behind its peers.
For Apollo Hospitals, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Apollo Hospitals (APOLLOHOSP), in Pharma & Healthcare.
- Over three months: Apollo Hospitals -5.9% against Pharma & Healthcare +1.4% (7.3 points behind).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Apollo HospitalsAPOLLOHOSP · Pharma & Healthcare | ₹8,446.00 | +0.9% | +6.7% | -5.9% | -6.9% | 0.7× | — |
Pharma & Healthcare
1M +3.0% · 3M +1.4%
Apollo Hospitals
Prices as of 6 Nov 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Aster DM Quality Care Q2 net profit more than doubles to ₹262 crore
Gland Pharma Q2FY27 results: Net profit rises 58% to ₹290.75 crore
Q2 results, order win drive Symbiotec Pharma 20% higher to new high
Fortis Q2 net profit falls 2.5% on higher expenses, lower exceptional gain
Glenmark Pharma Q2 revenue falls 30% to ₹4,247 crore, profit down 57%